The wrong question is "What age forces hormone replacement therapy to stop?"
The better question is "What is the reason to continue, and has the risk picture changed?"
Menopause Society says hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, and it can prevent bone loss and fracture. It also says risks differ by type, dose, duration, route, timing, and whether a progestogen is used. Continuing therapy should be reevaluated over time. [1]
That is not a blank check.
It is also not an automatic stop date.
Age 65 is not a cliff
American College of Obstetricians and Gynecologists says menopausal hormone therapy should not be used to prevent coronary heart disease. It also says some women age 65 and older may still need systemic hormone therapy for vasomotor symptoms, and it recommends against routine discontinuation of systemic estrogen at age 65. [2]
That sentence matters because many women hear "65" as a rule.
The actual clinical question is more personal.
Are hot flashes still severe? Is sleep still disrupted by night sweats? Is the dose low enough? Is the route oral or transdermal? Does the woman have a uterus? Has clot, stroke, breast, liver, or unexplained bleeding risk changed?
Systemic estrogen, progesterone, and progestins are prescription hormone decisions. They belong in clinician review, especially after 65.
Continuing after 65 is not the same as starting after 65
This distinction is the most important upgrade to the usual answer.
A woman who started hormone replacement therapy near menopause, still has severe night sweats without it, has no new contraindication, and understands the tradeoffs is asking a continuation question. A woman starting systemic estrogen for the first time at 68 for "anti-aging," weight, skin, or prevention is asking a much weaker question.
Geriatric prescribing guidance pushes the same caution from another angle. The 2023 American Geriatrics Society Beers Criteria apply to adults 65 and older and list medications that are often best avoided in older adults. The 2023 update says initiation of oral and transdermal estrogen should be avoided in older women, topical vaginal estrogen remains appropriate for major indications such as symptomatic vaginal atrophy or urinary tract infection prophylaxis, and deprescribing should be considered for older women already using nonvaginal estrogen. [6]
That does not cancel the American College of Obstetricians and Gynecologists point about avoiding routine discontinuation at 65. It adds the practical tension a clinician has to resolve: do not stop reflexively, but do not continue reflexively either.
Decision table: what the review should decide
| Review question | Why it matters after 65 | Safer decision frame |
|---|---|---|
| What symptom is still being treated? | Persistent hot flashes, night sweats, genitourinary syndrome of menopause, and bone-risk context are different goals. | Continue only for a named current goal, not vague prevention. |
| Is systemic therapy still needed? | Vaginal or urinary symptoms may respond to local options instead. | Compare systemic, local, and nonhormonal options. |
| What route and dose are being used? | Type, dose, route, timing, and progestogen use change risk. [1] | Use the lowest effective dose for the current goal. |
| Does she have a uterus? | Endometrial protection changes the regimen. | Confirm progesterone or progestin needs before continuing estrogen. |
| Has risk changed? | Age can raise baseline risks for clot, stroke, breast cancer, liver disease, and heart disease. | Recheck history, blood pressure, bleeding, and medication changes. |
| Scenario after 65 | Stronger case | Weaker case |
|---|---|---|
| Continuing systemic therapy | Severe recurrent vasomotor symptoms, documented benefit, low effective dose, no new contraindication, and annual review. [2] | Treatment continues because it has been on the medication list for years without a current indication. |
| Starting systemic therapy | Unusual, symptom-driven case after careful review of alternatives, route, dose, and baseline risk. | New start for anti-aging, cardiovascular prevention, cognition, metabolism, weight, skin, or general optimization. [2] [6] |
| genitourinary syndrome of menopause-only symptoms | Local vaginal estrogen or another local genitourinary syndrome of menopause option may match the symptom with less systemic exposure. [6] | A systemic pill or patch is used when the problem is isolated vaginal dryness or urinary symptoms. |
| Clot or stroke risk | Route and dose are reviewed after eligibility. | Transdermal route is treated as a way around prior deep vein thrombosis/pulmonary embolism, stroke, heart attack, thrombophilia, or unexplained bleeding. |
| Uterus present | Endometrial protection and bleeding rules are explicit. | Estrogen continues without a clear progestogen/endometrial plan. |
Women's Health Initiative still shapes the caution
The estrogen-plus-progestin Women's Health Initiative trial enrolled 16,608 postmenopausal women aged 50 to 79 with a uterus. The trial stopped early after a mean 5.2 years because the global risk-benefit index favored harm. The report found higher hazard ratios for coronary heart disease, stroke, pulmonary embolism, and invasive breast cancer, while hip fracture and colorectal cancer were lower. [3]
The estrogen-alone Women's Health Initiative trial enrolled 10,739 women with prior hysterectomy. Over 6.8 years, conjugated equine estrogen increased stroke risk and reduced hip fracture risk, with no overall chronic-disease prevention benefit. [4]
Those trials do not answer every modern route, dose, or product question.
They do explain why "staying on hormone replacement therapy forever for prevention" is not the clinical frame.
Mortality data do not remove the need for review
Longer Women's Health Initiative follow-up found that menopausal hormone therapy was not associated with all-cause, cardiovascular, or cancer mortality over 18 years in the pooled randomized trials. [5]
That is useful context.
It does not mean every woman should continue systemic therapy.
Mortality is not the only outcome that matters. Stroke, clot, breast symptoms, bleeding, quality of life, sleep, sexual comfort, and medication interactions still matter.
This is the evidence limits framing that matters: Women's Health Initiative follow-up can prevent exaggerated fear, but it does not turn systemic hormone replacement therapy into a prevention drug. The trials studied specific regimens and populations, and modern decisions still depend on route, dose, timing, uterus status, and personal contraindications.
Who it fits, and who should avoid rushing
Continuing hormone replacement therapy after 65 may fit a woman with persistent, bothersome vasomotor symptoms, a clear benefit, and no new contraindication after review. It may also fit selected women who need individualized bone-risk discussion and understand that systemic hormone therapy is not a chronic-disease-prevention plan.
It is usually a weaker fit when the only goal is anti-aging, general wellness, metabolism, or skin. It should be reviewed carefully when there is unexplained bleeding, new breast symptoms, clot or stroke history, coronary disease, active liver disease, migraine complexity, smoking plus vascular risk, or major medication changes.
A current estradiol/norethindrone acetate label lists contraindications that include undiagnosed abnormal genital bleeding, breast cancer or history of breast cancer, estrogen-dependent neoplasia, active deep vein thrombosis or pulmonary embolism or history of those conditions, active arterial thromboembolic disease such as stroke or heart attack or history of those conditions, hepatic impairment or disease, and known thrombophilic disorders. [7]
Those label contraindications matter more after 65 because baseline vascular and cancer risks are more likely to have changed since the prescription first started.
Red flags that should change the plan
Postmenopausal bleeding, new breast mass or concerning breast symptoms, chest pain, sudden shortness of breath, one-sided leg swelling, sudden neurologic symptoms, severe new headache, vision loss, jaundice, or signs of allergic reaction should not wait for the next annual review.
Less urgent but still important review triggers include a new migraine pattern, rising blood pressure, new smoking status, upcoming major surgery or immobilization, new atrial fibrillation or anticoagulant use, abnormal liver testing, or a change in cancer or clot history.
For route-specific clot-risk counseling, see transdermal versus oral estrogen and clot risk.
What to ask a clinician
Ask:
- What exact symptom or risk are we treating now?
- Could a lower dose, transdermal route, local vaginal therapy, or nonhormonal option fit better?
- Do I need progesterone or a progestin because I have a uterus?
- What bleeding pattern, breast symptom, clot symptom, stroke symptom, or blood-pressure change should make me stop and call?
- When is the next review, and what would make us taper, switch, or continue?
Bottom line
Hormone replacement therapy after 65 is not automatically wrong.
It is a reason to tighten the review.
A defensible plan names the symptom target, uses the lowest effective dose for the current goal, checks whether local or nonhormonal options could replace systemic therapy, and revisits risk at least yearly.
If the only reason to continue is "anti-aging," "metabolism," or "general wellness," the evidence case is weak.
If the reason is persistent symptoms and the risk profile still fits, continued therapy can be a clinician-led decision rather than an age-rule failure.
Related reading:
- hormone replacement therapy After Hysterectomy.
- Micronized Progesterone for Sleep After Menopause.
- Ospemifene After Menopause.
- Starting hormone replacement therapy After 60.
References
[1] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[2] ACOG Committee Opinion No. 565: Hormone therapy and heart disease. Obstet Gynecol. 2013;121(6):1407-1410. doi:10.1097/01.aog.0000431053.33593.2d https://pubmed.ncbi.nlm.nih.gov/23812486/
[3] Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. doi:10.1001/jama.288.3.321 https://pubmed.ncbi.nlm.nih.gov/12117397/
[4] Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-12. doi:10.1001/jama.291.14.1701 https://pubmed.ncbi.nlm.nih.gov/15082697/
[5] Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938. doi:10.1001/jama.2017.11217 https://pubmed.ncbi.nlm.nih.gov/28898378/
[6] By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 https://pubmed.ncbi.nlm.nih.gov/37139824/
[7] DailyMed. Estradiol and norethindrone acetate tablet prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c786d6-91bd-4eea-9455-ff2abc08372f